Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1578 | IgG test Wiki | 0.41 |
drug507 | Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation Wiki | 0.41 |
drug765 | Clinical Trial Matching Wiki | 0.41 |
Name (Synonyms) | Correlation | |
---|---|---|
drug3977 | questionnaire and optional interview Wiki | 0.41 |
drug1204 | Exercise booklet Wiki | 0.41 |
drug1010 | Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta Wiki | 0.41 |
drug610 | COVID-19 convalescent plasma Wiki | 0.18 |
Name (Synonyms) | Correlation | |
---|---|---|
D016889 | Endometrial Neoplasms NIH | 0.41 |
D004938 | Esophageal Neoplasms NIH | 0.41 |
D013274 | Stomach Neoplasms NIH | 0.41 |
Name (Synonyms) | Correlation | |
---|---|---|
D012878 | Skin Neoplasms NIH | 0.41 |
D009423 | Nervous System Neoplasms NIH | 0.41 |
D007680 | Kidney Neoplasms NIH | 0.41 |
D016543 | Central Nervous System Neoplasms NIH | 0.41 |
D005909 | Glioblastoma NIH | 0.41 |
D008113 | Liver Neoplasms NIH | 0.41 |
D007822 | Laryngeal Neoplasms NIH | 0.41 |
D013736 | Testicular Neoplasms NIH | 0.41 |
D002292 | Carcinoma, Renal Cell NIH | 0.29 |
D002583 | Uterine Cervical Neoplasms NIH | 0.29 |
D012004 | Rectal Neoplasms NIH | 0.29 |
D018281 | Cholangiocarcinoma NIH | 0.29 |
D018358 | Neuroendocrine Tumors NIH | 0.29 |
D008545 | Melanoma NIH | 0.24 |
D010190 | Pancreatic Neoplasms NIH | 0.24 |
D006258 | Head and Neck Neoplasms NIH | 0.24 |
D002277 | Carcinoma NIH | 0.20 |
D003110 | Colonic Neoplasms NIH | 0.20 |
D001943 | Breast Neoplasms NIH | 0.18 |
D003141 | Communicable Diseases NIH | 0.03 |
D007239 | Infection NIH | 0.02 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
D018352 | Coronavirus Infections NIH | 0.01 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100526 | Neoplasm of the lung HPO | 1.00 |
HP:0002896 | Neoplasm of the liver HPO | 0.41 |
HP:0008069 | Neoplasm of the skin HPO | 0.41 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012114 | Endometrial carcinoma HPO | 0.41 |
HP:0100006 | Neoplasm of the central nervous system HPO | 0.41 |
HP:0010788 | Testicular neoplasm HPO | 0.41 |
HP:0009726 | Renal neoplasm HPO | 0.41 |
HP:0012174 | Glioblastoma multiforme HPO | 0.41 |
HP:0100751 | Esophageal neoplasm HPO | 0.41 |
HP:0004375 | Neoplasm of the nervous system HPO | 0.41 |
HP:0006753 | Neoplasm of the stomach HPO | 0.41 |
HP:0100605 | Neoplasm of the larynx HPO | 0.41 |
HP:0005584 | Renal cell carcinoma HPO | 0.29 |
HP:0100634 | Neuroendocrine neoplasm HPO | 0.29 |
HP:0100743 | Neoplasm of the rectum HPO | 0.29 |
HP:0030153 | Cholangiocarcinoma HPO | 0.29 |
HP:0030079 | Cervix cancer HPO | 0.29 |
HP:0002894 | Neoplasm of the pancreas HPO | 0.24 |
HP:0012288 | Neoplasm of head and neck HPO | 0.24 |
HP:0012056 | Cutaneous melanoma HPO | 0.24 |
HP:0030731 | Carcinoma HPO | 0.20 |
HP:0003003 | Colon cancer HPO | 0.20 |
HP:0003002 | Breast carcinoma HPO | 0.18 |
Navigate: Correlations HPO
There are 6 clinical trials
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Description: CTE Accrual
Measure: Proportion of patients Eligible for CTE versus Actual CTE Time: Through study completion, an average of 1 yearDescription: OS
Measure: Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: PFS
Measure: Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire
Measure: Identification of Barriers to CTE Time: Through study completion, an average of 1 yearDescription: To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).
Measure: Real World Data Analytics Time: Through study completion, an average of 1 yearDescription: VTB Use Rate
Measure: Virtual Tumor Board Utilization Time: Through study completion, an average of 1 yearDescription: Time to CTE
Measure: Time from Intervention to Actual CTE (months) Time: Through study completion, an average of 1 yearThis is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members. The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.
Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.
Measure: Clinical data of lung cancer patients with COVID-19 diagnoses Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsDescription: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis
Measure: Diagnosis data Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsDescription: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as treatments received
Measure: Treatments received Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsDescription: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as prognostic factors.
Measure: Prognostic factors Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsThe unexpected onset of SARS-COV2 infection modified our practices, especially in routine medicine. In order to reverse the epidemic curve of severe cases and slow the spread of the infection, confinement was generalized in France from March 13, 2020.These restrictive measures were imposed on anyone with symptoms compatible with the infection, with the exception of dyspnea and other criteria of severity. March 12, 2020 is the pivotal date when the management of COVID came to interfere with medical and healthcare organizations. From this date, it is likely that some imaging or endoscopic exams have been de-scheduled for symptoms that are sometimes wrongly judged to be non-urgent and have seen their numbers drop dramatically.Otherwise, concerning lung cancer, preventive measures have been extremely strengthened. For instance, it is recommended to delay surgeries for localized tumors, to relieve or remove some chemotherapy or to delete radiotherapy sessions deemed non-essential. However, symptoms that may initially be attributed to viral infection, such as cough, fever, fatigue, or chest pain may be clinical indicators of early-stage Lung cancer. In addition, lung cancer is likely to make the patient more susceptible to pneumopathy, due to a weakened of immune response to viruses and bacteria. Consequently, as necessary as the restriction measures are, a risk of slowing down in the management of the Lung cancer pathology exists. The CBP-COVID Study intends to assess consequences of restrictive measures linked to the SARS-COV2 epidemic, by comparing clinical characteristics at diagnosis, treatment times and treatments, regarding to 2 distinct time periods identical to the calendar, but one in 2019, the other in 2020.
Description: Comparison Group 2019 versus Group 2019
Measure: Comparison of clinical characteristics Time: At the end of the second period, i.e. on August 28, 2020Description: Comparison Group 2019 versus Group 2020
Measure: Comparison of diagnostic procedures Time: At the end of the second period, i.e. on August 28, 2020Description: Comparison Group 2019 versus Group 2020
Measure: Comparison of treatments (according to stage of disease) Time: At the end of the second period, i.e. on August 28, 2020Description: Comparison Group 2019 versus Group 2020
Measure: Comparison of patients management deadlines Time: At the end of the second period, i.e. on August 28, 2020Description: Comparison Group 2019 versus Group 2020
Measure: Comparison of survival Time: After 2 years post diagnosesObservational, retrospective data collection and prospective IgG analysis, and multicenter study. The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection. For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.
Description: Description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection.
Measure: Description of the characteristics of patients Time: From the diagnosis of the COVID until the determination of the blood IgGs, up to 10 weeksDuring the COVID-19 pandemic, people's lives have changed dramatically. People with lung cancer who are shielding may have been particularly affected as they may be unable to carry out many of their normal daily activities, such as grocery shopping and exercise, and are unable to interact with friends and family. People with lung cancer will also have experienced some changes to the clinical services available to them at The Christie. Using a questionnaire and interviews, the investigators want to understand patient experiences of the changes in their daily lives and the changes to their clinical care. This will help us to see if people with lung cancer need any additional support services or if there are any changes the investigators can make to clinical services to improve patient experiences. Eligible patients will be any lung cancer patients receiving current treatment or in active follow up.
Description: Physical and social impact will be captured by the EuroQual-5D quality of life and questions regarding patient's diagnosis and treatment pathway including a list of symptoms based on the Common Terminology Criteria for Adverse Events.
Measure: Physical and Social impact Time: baselineDescription: Emotional impact will be assessed using the Hospital Anxiety Depression Scale. Scores range from 0-21 for each of the two subscales (anxiety and depression), with higher scores indicating greater anxiety and depression.
Measure: Psychological impact Time: baselineDescription: Frailty will be assessed using the Rockwood Clinical Frailty Scale. With scores ranging from 1-9, with higher scores indicating higher frailty.
Measure: prevalence and impact of frailty Time: baselineIn this study, providing access to physiotherapy applications by telerehabilitation method and the effectiveness of this application will be examined for patients who have undergone lung surgery in the early postoperative period during the pandemic process in which social isolation continues.
Description: Major complication rates such as postoperative fever, infection, and hemorrhage will be documented.
Measure: Major complication rate Time: Up to 3 monthsDescription: The six-minute walking test is an example of timed distance testing, widely used in clinical research and rehabilitation studies. According to the guidelines published by the American Thoracic Society, 6MWT is an easy-to-use, better tolerated test that reflects daily activities better than other walking tests. It can be applied in a short time. Requires little equipment. The six-minute walk test, used as a field test, is a simple and inexpensive test compatible with daily activities, which does not require exercise equipment. Before starting the test, the patient should rest for at least 10 minutes by sitting in the chair near the starting point. The walking area must be at least 30 m long. A shorter corridor causes more time to be spent for more frequent turns and changes of direction. With the help of stopwatch, it is kept for 6 minutes and the number of laps during the period is calculated and recorded. The functional capacity of the cases will be evaluated with 6MWT.
Measure: The six-minute walking test Time: Up to 3 monthsDescription: It is a scale used to determine the severity of dyspnea with a rating of zero to 4. Zero means no dyspnea perception and 4 means severe dyspnea.
Measure: Modified Medical Research Council Dyspnea Scale Time: Up to 3 monthsDescription: The pain, dyspnea and fatigue level of the cases were evaluated with visual analog scale (VAS) score. The scale presented as a 100 mm horizontal ruler is a documented method for scoring continuous soft data. "0" score means no pain, "100" means very severe pain
Measure: Visual analog scale Time: Up to 3 monthsDescription: FEV1 measurements will be reported as absolute values (e.g. liters, measured) and percentage of predicted (FEV1measured/ FEV1 predicted).
Measure: Forced expiratory volume one second (FEV1) Time: Up to 3 monthsDescription: FVC measurements will be reported as absolute values (e.g. liters, measured) and percentage of predicted (FVCmeasured/ FVC predicted).
Measure: Forced vital capacity (FVC) Time: Up to 3 monthsDescription: DLCO and DLCO / VA values will be analyzed
Measure: Diffusion Capacity Time: Change from baseline to 1 and 3 monthsDescription: Lung capacities will be given the measured value and their percentages will be calculated according to the estimated values.
Measure: Lung Capacities Time: Change from baseline to 1 and 3 monthsDescription: Tumor side and contralateral lung V / Q scintigraphy measurements will be made.
Measure: Lung V/Q Scintigraphy Time: Change from baseline to 1 and 3 monthsDescription: Procalcitonin is a substance produced by many types of cells in the body, often in response to bacterial infections but also in response to tissue injury. The level of procalcitonin in the blood can increase significantly in systemic bacterial infections and sepsis.The reference value of PCT in adults and children older than 72 hours is 0. 15 ng/mL or less.
Measure: Procalcitonin (PCT) Time: Up to 3 monthsDescription: C-reactive protein is a substance produced by the liver in response to inflammation. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L). A test result showing a CRP level greater than 10 mg/L is a sign of serious infection, trauma or chronic disease, which likely will require further testing to determine the cause
Measure: C-Reactive Protein (CRP) Time: Up to 3 monthsDescription: Ferritin is a blood protein that contains iron. The normal ferritin levels range from 12 to 300 nanograms per milliliter of blood (ng/mL) for males and 12 to 150 ng/mL for females.
Measure: Ferritin Time: Up to 3 monthsDescription: Lactate dehydrogenase is an enzyme that helps turn sugar into energy for your cells. High LDH levels could indicate cell damage.Normal LDH levels range from 140 units per liter (U/L) to 280 U/L or 2.34 microkatals/L to 4.68 microkatals/L.
Measure: Lactate dehydrogenase Time: Up to 3 monthsDescription: D-dimer tests are used to help rule out the presence of an inappropriate blood clot (thrombus). The reference concentration of D-dimer is < 250 ng/mL, or < 0.4 mcg/mL.
Measure: D'dimer test Time: Up to 3 monthsDescription: The partial pressure of carbon dioxide (PCO2) is the measure of carbon dioxide within arterial or venous blood. It often serves as a marker of sufficient alveolar ventilation within the lungs. Generally, under normal physiologic conditions, the value of PCO2 ranges between 35 to 45 mmHg.
Measure: Partial Carbon monoxide Pressure (PaCO2) Time: Up to 3 monthsDescription: The partial pressure of oxygen, also known as PaO2, is a measurement of oxygen pressure in arterial blood. 75 to 100 millimeters of mercury (mm Hg) is the normal ranges.
Measure: Partial Oxigen Pressure (PaO2) Time: Up to 3 monthsDescription: It reflects the saturation level of hemoglobin with oxygen. Its normal values are 95-100%.
Measure: Arterial blood oxygen saturation level (SaO2) Time: Up to 3 monthsDescription: The state-trait anxiety scale will determine the anxiety levels of patients before and after surgery. It is a psychological inventory based on a 4-point Likert scale and consists of 40 questions on a self-report basis. The STAI measures two types of anxiety - state anxiety, or anxiety about an event, and trait anxiety, or anxiety level as a personal characteristic.While evaluating, a score between 1 (or -1) and 4 (or -4) is given for each item according to the positive or negative characteristics of the item, and the total score to be obtained is 50 constant is added. The highest score is 80, the lowest is 20. Total anxiety the higher the score, the more anxiety level of the person filling the scale.
Measure: Anxiety inventory Time: Up to 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports